View as Web Page

   March 2018

Arnall Golden Gregory LLP's Food and Drug Newsletter is a monthly update of legal and regulatory issues that affect the FDA-regulated community, including regular updates on legislative initiatives from AGG’s Washington, DC office, and articles from members of AGG outside the Food and Drug Practice.

In this Issue

 Industry Insights



Don’t You Forget About Me: FDA Kicks off 2018 with Letters on Promotional Activities
By: Alan G. Minsk and Elizabeth A. Mulkey

FDA’s Office of Prescription Drug Promotion (OPDP) issued only five letters in 2017 (compared to eleven in 2016 and nine in 2015). This relatively slow year left some prescription drug manufacturers wondering if, to quote the classic Simple Minds 1980s song, FDA would “call their names, or walk on by” promotional activities that might have previously drawn a Warning Letter or Untitled Letter. In February, the agency reassured industry that it hasn’t forgotten about promotional activities, issuing one letter from OPDP, and one from the Center for Biologics Evaluation and Research (CBER). More > 

Top 5 Reasons for Life Sciences Companies to Use International Arbitration for Intellectual Property Disputes
By: Gene M. Burd

Arbitration continues gaining popularity for resolution of cross-border disputes. A 2013 PricewaterhouseCoopers survey shows that 52% of the respondents preferred international arbitration to court litigation and mediation. Over the past 10 years, the number of new cases in most of the major arbitration institutions grew, with some reporting almost a four-fold increase. The International Chamber of Commerce (ICC), for instance, reported a record 2016 year for new arbitrations with 966 new cases, which is up from 801 cases in the previous year and 793 cases in 2010. ICC also reported a record number of pending cases in 2017, suggesting that the upward trend will continue. More > 



Checklists and Guidance from FDA on the Acceptance Criteria for 510(k) Submissions
By: Deborah L. Livornese and Kalie E. Richardson

FDA recently issued a final guidance on the Refuse to Accept Policy for 510(k)s (Guidance). The Guidance outlines the procedures and criteria FDA uses to determine whether a medical device premarket notification (510(k)) submission is administratively complete and should be accepted for substantive review. The criteria for traditional, special, and abbreviated 510(k) submissions are covered by the Guidance. The Guidance also includes, as appendices, the Acceptable Checklists FDA will use to evaluate all 510(k) types. More >

It’s the Journey, Not Just the Destination: FDA Says Have a Procedure, Use the Procedure, or Go Back and Do It from the Beginning
By: Deborah L. Livornese

The Food and Drug Administration recently posted a Warning Letter issued to a medical device manufacturer following a facility inspection citing a laundry list of alleged violations related to the company’s Corrective and Preventative Action (CAPA) procedures and Quality System Regulations (QSRs) processes. More >

 Industry Activities and Recognition
Arnall Golden Gregory LLP is proud to announce that two of its FDA attorneys are winners of JD Supra’s Readers’ Choice Awards, which recognize authors whose content enjoys a high level of reader engagement. Partner Alan G. Minsk and Of Counsel Deborah L. Livornese were honored for their life sciences articles. Partner Montserrat C. Miller was honored for her articles on employer liability issues. JD Supra delivers attorney content to executives, in-house counsel, lawyers, journalists and other target readers. In 2017, nearly 50,000 authors published their insights and commentary on JD Supra. Only 242 thought leaders were selected from that mix for achieving the highest visibility and engagement for their particular expertise last year.

Upcoming Events 

AGG Partner Alan G. Minsk will be speaking about FDA-related advertising and promotional issues to a pharmaceutical client on April 9, 2018 in San Diego, CA.

AGG Attorney Deborah L. Livornese will present "Regulation of Over-the-Counter (OTC) Drugs" at the Food and Drug Law Institute's Introduction to US Drug Law and Regulation on April 13, 2018 in Washington, DC.

AGG Partner Alan G. Minsk will present at the “Short Course: Sample Compliance & the PDMA,” sponsored by The Sharing Alliance (formerly known as the PDMA Alliance) on April 20, 2018 in New Jersey.

AGG Attorney Deborah L. Livornese will be speaking on the session "OTC Drug Monograph Reform" at the Food and Drug Law Institute's 2018 Annual Conference on May 4, 2018 in Washington, DC.

This newsletter is published by Arnall Golden Gregory’s Food and Drug and Government Affairs and Public Policy Practices. This information presented provides a general summary of recent legal and regulatory developments. It is not intended to be, and should not be relied upon, as legal advice. For more information about the Food and Drug Practice, please contact Alan Minsk.
©2018. Arnall Golden Gregory LLP. All Rights Reserved.  Atlanta | Washington, DC

 Comments | Manage your SubscriptionForward to a Friend | Unsubscribe